Chairman's share sale at current price is concerning. No insider buying in the last year and history of sales make us cautious. Company not recommended for buying now.
The company's record-breaking performance and strong demand in key markets have led to a positive outlook for 2024. The strategic partnerships with Oshkosh and SANY could potentially boost the company's Q1 2024 results.
Allison Transmission Holdings' efficient capital allocation generates impressive returns, but it isn't compounding its base of capital, a characteristic of a multi-bagger. Thus, it's unlikely to be a multi-bagger going forward. Investors seeking a multi-bagger might find better luck elsewhere.
Allison Transmission Holdings' low P/E ratio is due to its lower forecast growth compared to the wider market. Investors expect limited future growth, making a strong rise in share price unlikely.
Despite high profitability from capital, Allison Transmission Holdings isn't expanding it. The 5-year stock performance may mirror this, possibly limiting its multi-bagger potential.
ACT Research released preliminary NA truck net orders for July 2023. Class 8 net orders were 16,000 units, down 5% MoM and up 45% YoY (on an easy compare). Seasonally adjusted net orders came in at 20,700 units (248,400 SAAR), up 5.5% MoM. July tends to be a seasonally weak month for orders, and order activity was in-line with ACT Research’s expectations. Per ACT, the July data implies Class 8...
Gainers: •$Akero Therapeutics(AKRO.US)$+9.6% (announces two financing transactions with Pfizer (PFE) and Hercules Capital (HTGC) providing access to up to $125 million) •$BrightSpire Capital(BRSP.US)$+6.3% (increases dividend) •$Humanigen(HGEN.US)$+4% (entered into an agreement with PCI Pharma Services as part of preparations for commercialization in the United Kingdom) •$艾里遜變速箱(ALSN.US)$+2.8% (electric hybrid bu...
艾里遜變速箱股票討論區
專欄Preliminary Truck Orders | July NA Class 8 Net Orders 16,000 Units, Down 5% MoM & Up 45% YoY - JP Morgan
毛利率5年來波動下滑到47.7%,淨資產收益率非常高,除2020年低至39%之外,其餘4年都在57%到95%之間。
5年來營收除2020年暴跌23%之外基本保持增長,5年總體增長很少,營業利潤則在2020年暴跌了40%,2021年僅少量恢復,淨利潤2020年暴跌51%,2021年部分恢復。
2022前兩季度營收增長12.6%,營業利潤增長12.1%,淨利潤增長9.1%,
利潤表顯示2021年利息費用佔營業利潤的17%,負擔不低,其它收入科目佔比很低,利潤表比較乾淨。
5年來資產負債率一直在83.6%高位上下波動,應收帳款和存貨水平有所增長,增速和比例都在正常範圍。
商譽達到了21億,佔淨資產7.49億的280%,長期借款25.04億,佔淨資產的334%。注意淨資產其實是靠商譽,實際槓桿率已經無法計算。
目前市盈率8.1,市盈率TTM 7.2,考慮到過高的槓桿率,還是等負債降低些再説。
專欄Today's pre-market stock movers: KR, REV, RACE, PHG and more
• $Akero Therapeutics(AKRO.US)$ +9.6% (announces two financing transactions with Pfizer (PFE) and Hercules Capital (HTGC) providing access to up to $125 million)
• $BrightSpire Capital(BRSP.US)$ +6.3% (increases dividend)
• $Humanigen(HGEN.US)$ +4% (entered into an agreement with PCI Pharma Services as part of preparations for commercialization in the United Kingdom)
• $艾里遜變速箱(ALSN.US)$ +2.8% (electric hybrid bu...
暫無評論